Home

MTSR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Metsera, Inc. Is Fair to Shareholders

via Business Wire

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Metsera, Inc. (NASDAQ: MTSR) to Pfizer Inc. is fair to Metsera shareholders. Under the terms of the proposed transaction, Metsera shareholders will receive $47.50 per share in cash at closing, plus a non-transferable contingent value right entitling holders to potential additional payments of up to $22.50 per share in cash tied to three specific clinical and regulatory milestones.

Halper Sadeh encourages Metsera shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.

The investigation concerns whether Metsera and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Metsera shareholders; (2) determine whether Pfizer is underpaying for Metsera; and (3) disclose all material information necessary for Metsera shareholders to adequately assess and value the merger consideration.

On behalf of Metsera shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contacts